These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 6791053)
41. Hyperammonemia associated with valproic acid use in elderly psychiatric patients. Holroyd S; Overdyke JT J Neuropsychiatry Clin Neurosci; 2012; 24(3):372-4. PubMed ID: 23037652 [TBL] [Abstract][Full Text] [Related]
42. Valproic Acid-Associated Hyperammonemia: A Systematic Review. Wong YJ; Fan J; Wan A; Mihic T; Gnyra M J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):283-294. PubMed ID: 37126830 [TBL] [Abstract][Full Text] [Related]
43. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure. Panda S; Radhakrishnan K J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456 [TBL] [Abstract][Full Text] [Related]
44. [Ring chromosome 20, hypersensitivity to valproate and hyperammonemic encephalopathy]. Ortiz-Sáenz de Santa María MR; Barriuso-Pérez E; Soto-Alvarez MI; Moche-Loeri JA Rev Neurol; 2003 Oct 16-31; 37(8):733-5. PubMed ID: 14593631 [TBL] [Abstract][Full Text] [Related]
51. Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. Thomas KL; La AQ; Punia S; Doroudgar S; Perry PJ Ann Clin Psychiatry; 2016 Feb; 28(1):37-42. PubMed ID: 26855984 [TBL] [Abstract][Full Text] [Related]
52. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia. Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087 [TBL] [Abstract][Full Text] [Related]
53. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012. Cheng M; Tang X; Wen S; Yue J; Wang H Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073 [TBL] [Abstract][Full Text] [Related]
54. [Carglumic acid for treatment of valproic acid-induced hyperammonaemia in a paediatric patient]. Gramage Caro T; Vélez-Díaz-Pallarés M; Serna Pérez J; Bermejo Vicedo T Farm Hosp; 2012; 36(5):437-8. PubMed ID: 22858088 [No Abstract] [Full Text] [Related]
55. [Hyperammonaemic encephalopathy due to valproic acid in the neonatal period]. Jiménez-Parrilla F; Pérez-Sánchez A; Núñez-Solís JM; Madruga-Garrido M; Losada-Martínez A Rev Neurol; 2009 Jun 1-15; 48(11):613-4. PubMed ID: 19472163 [No Abstract] [Full Text] [Related]
56. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist? Chicharro AV; de Marinis AJ; Kanner AM Epilepsy Behav; 2007 Nov; 11(3):361-6. PubMed ID: 17845866 [TBL] [Abstract][Full Text] [Related]
59. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182 [TBL] [Abstract][Full Text] [Related]
60. Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey. Hosseini H; Shafie M; Shakiba A; Ghayyem H; Mayeli M; Hassani M; Aghamollaii V Psychopharmacology (Berl); 2023 Jan; 240(1):149-156. PubMed ID: 36459199 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]